Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

EBV reactivation serological profile in primary Sjogren's syndrome: an underlying trigger of active articular involvement?

Texto completo
Autor(es):
Pasoto, Sandra Gofinet [1, 2] ; Natalino, Renato Romera [2] ; Chakkour, Henrique Pires [2] ; Trindade Viana, Vilma dos Santos [2] ; Bueno, Cleonice [2] ; Leon, Elaine Pires [2] ; Gualhardo Vendramini, Margarete Borges [2] ; Levy Neto, Mauricio [2] ; Bonfa, Eloisa [2]
Número total de Autores: 9
Afiliação do(s) autor(es):
[1] Univ Sao Paulo, Disciplina Reumatol, Fac Med, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Div Rheumatol, Fac Med, Hosp Clin, BR-01246903 Sao Paulo - Brazil
Número total de Afiliações: 2
Tipo de documento: Artigo Científico
Fonte: RHEUMATOLOGY INTERNATIONAL; v. 33, n. 5, p. 1149-1157, MAY 2013.
Citações Web of Science: 17
Resumo

Antibody to Epstein-Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations with clinical/therapeutic features in primary Sjogren's syndrome (pSS) were not established. We evaluated 100 pSS patients (American-European Criteria) and 89 age/gender/ethnicity-matched healthy controls. Disease activity was measured by EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI). Antibodies to EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) were determined by ELISA. Patients and controls had comparable frequencies and mean levels of anti-VCA IgG (90 vs. 86.5 %, p = 0.501; 2.6 +/- A 1.1 vs. 2.5 +/- A 1.1 AU/mL, p = 0.737) and anti-EBNA-1 IgG (92 vs. 94.4 %, p = 0.576; 141.3 +/- A 69.8 vs. 135.6 +/- A 67.5 RU/mL, p = 0.464). Anti-VCA IgM was negative in all cases. Noteworthy, higher frequency and increased mean levels of anti-EA-D were observed in patients than controls (36 vs. 4.5 %, p < 0.0001; 38.6 +/- A 57.4 vs. 7.9 +/- A 26.3 RU/mL, p < 0.0001). Further analysis of patients with (n = 36) and without (n = 64) anti-EA-D revealed comparable age/gender/ethnicity (p a parts per thousand yen 0.551), current prednisone dose (4.8 +/- A 6.9 vs. 5.1 +/- A 10.4 mg/day, p = 0.319), and current uses of prednisone (52.8 vs. 37.5 %, p = 0.148) and immunosuppressants (44.4 vs. 31.3 %, p = 0.201). ESSDAI values were comparable (p = 0.102), but joint activity was more frequent (25 vs. 9.4 %, p = 0.045) in anti-EA-D positive patients. Anti-EA-D antibodies were not associated with anti-Ro/SSA (p = 1.000), anti-La/SSB (p = 0.652), rheumatoid factor (p = 1.000), anti-alpha-fodrin (p = 0.390) or antiphospholipid antibodies (p = 0.573), not suggesting cross-reactivity. The higher anti-EA-D frequency associated with joint activity raises the possibility that a subclinical EBV reactivation may trigger or perpetuate the articular involvement in pSS. (AU)

Processo FAPESP: 10/10013-4 - Autoanticorpos séricos da síndrome de Sjögren primária: estudo das associações clínicas e das possíveis correlações com anticorpos dirigidos a antígenos virais: vírus Epstein-Barr e Human T Leukemia virus 1
Beneficiário:Sandra Gofinet Pasoto
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 10/10017-0 - Autoanticorpos séricos na Síndrome de Sjogren primária: estudo das associações clínicas e das possíveis correlações com anticorpos dirigidos a antígenos virais - vírus Epstein-Barr e "Human T Leukemia vírus 1"
Beneficiário:Renato Romera Natalino
Linha de fomento: Bolsas no Brasil - Iniciação Científica
Processo FAPESP: 10/13463-0 - Anticorpos antifosfolípides na Síndrome de Sjogren primária: prevalência e associações clínicas
Beneficiário:Henrique Pires Chakkour
Linha de fomento: Bolsas no Brasil - Iniciação Científica